Literature DB >> 23474311

Algorithms for identification of Guillain-Barré Syndrome among adolescents in claims databases.

Donnie Funch1, Crystal Holick, Priscilla Velentgas, Robin Clifford, Peter M Wahl, Cheryl McMahill-Walraven, Patricia Gladowski, Richard Platt, Anthony Amato, K Arnold Chan.   

Abstract

BACKGROUND: Health insurance claims databases can provide data for studies of vaccine-related Guillain-Barre' Syndrome (GBS), but not all patients with a diagnostic ICD-9-CM code for GBS have the disease. The objective of this study was to evaluate the positive predictive values (PPVs) of claims-based algorithms for identifying GBS cases in 4 claims database environments.
METHODS: Potential cases were adolescents ages 11-21 with at least one claim for GBS (ICD-9-CM code 357.0). Medical record reviews by a panel of 3 neurologists were conducted for case confirmation. Claims data considered for inclusion in the case-ascertainment algorithm included coding position, physician specialty, visit type, diagnostic tests. PPVs were used to assess the contribution of study factors in predicting case status.
RESULTS: Among 361 individuals with a GBS diagnosis code, 106 were confirmed overall (PPV=0.29), varying from 0.24 to 0.56 across the 4 sites. Requiring the GBS code to be associated with a neurologist visit (PPV=0.53) or to be in a primary position on an inpatient claim (0.56) improved the performance. A composite algorithm including a primary inpatient GBS code and a neurologist visit associated with any GBS code gave the highest PPV (0.70). Incorporating claims for diagnostic testing had little impact on the PPV. Findings were generally similar across study sites.
CONCLUSIONS: Algorithms were able to identify GBS cases better than the single occurrence of the diagnostic code for GBS, and these algorithms may perform similarly in different claims environments.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23474311     DOI: 10.1016/j.vaccine.2013.02.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Prenatal Tdap immunization and risk of maternal and newborn adverse events.

Authors:  J Bradley Layton; Anne M Butler; Dongmei Li; Kim A Boggess; David J Weber; Leah J McGrath; Sylvia Becker-Dreps
Journal:  Vaccine       Date:  2017-06-29       Impact factor: 3.641

2.  Quantitative Bias Analysis in Regulatory Settings.

Authors:  Timothy L Lash; Matthew P Fox; Darryl Cooney; Yun Lu; Richard A Forshee
Journal:  Am J Public Health       Date:  2016-05-19       Impact factor: 9.308

3.  Lack of Association of Spontaneous Coronary Artery Dissection With Autoimmune Disease.

Authors:  Vanessa L Kronzer; Alex D Tarabochia; Angie S Lobo Romero; Nicholas Y Tan; Thomas J O'Byrne; Cynthia S Crowson; Tamiel N Turley; Elena Myasoedova; John M Davis; Claire E Raphael; Rajiv Gulati; Sharonne N Hayes; Marysia S Tweet
Journal:  J Am Coll Cardiol       Date:  2020-11-10       Impact factor: 24.094

4.  Assessment of text documentation accompanying uncoded diagnoses in computerized health insurance claims in Japan.

Authors:  Shinichi Tanihara
Journal:  J Epidemiol       Date:  2015-02-07       Impact factor: 3.211

5.  Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care data.

Authors:  Iain M Carey; Emma Banchoff; Niranjanan Nirmalananthan; Tess Harris; Stephen DeWilde; Umar A R Chaudhry; Derek G Cook
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

6.  Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database.

Authors:  Enrique Alcalde-Cabero; Javier Almazán-Isla; Fernando J García López; José Ramón Ara-Callizo; Fuencisla Avellanal; Carlos Casasnovas; Carlos Cemillán; José Ignacio Cuadrado; Jacinto Duarte; María Dolores Fernández-Pérez; Óscar Fernández; Juan Antonio García Merino; Rosa García Montero; Dolores Montero; Julio Pardo; Francisco Javier Rodríguez-Rivera; María Ruiz-Tovar; Jesús de Pedro-Cuesta
Journal:  BMC Neurol       Date:  2016-05-21       Impact factor: 2.474

7.  Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.

Authors:  Najat J Ziyadeh; Anja Geldhof; Wim Noël; Marijo Otero-Lobato; Suzan Esslinger; Soumya D Chakravarty; Yiting Wang; John D Seeger
Journal:  Clin Drug Investig       Date:  2020-11       Impact factor: 2.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.